| Name | Title | Contact Details |
|---|
Telik is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Carbon Sciences Inc. is developing a breakthrough technology to transform carbon dioxide (CO2) emissions into the basic fuel building blocks required to produce gasoline, diesel fuel, jet fuel and other portable fuels.
Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its lead oral drug candidate for a potentially curative treatment of HBV infections.
ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA`s lead development program is intended to be a direct implementation of those ideas. Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF). ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted prevention treatment for AF. ARCA is also developing rNAPc2 as potential treatment for RNA-associated diseases, initially focused on COVID-19.
Exagen Diagnostics, Inc. is committed to providing excellent service to our physicians, patients and partners.